Zynerba Pharmaceuticals (United States)

Recent papers from Zynerba Pharmaceuticals (United States)

1. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatmentJournal of Neurodevelopmental Disorders · 2023
2. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)Journal of Neurodevelopmental Disorders · 2022
3. Adjunctive Transdermal Cannabidiol for Adults With Focal EpilepsyJAMA Network Open · 2022
4. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic EncephalopathiesJAMA Network Open · 2021
5. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndromeJournal of Neurodevelopmental Disorders · 2019
6. Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the LiteratureCannabis and Cannabinoid Research · 2019